Biomea Fusion Inc. (BMEA) PT Raised to $50 at H.C. Wainwright

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Biomea Fusion Inc. (BMEA) PT Raised to $50 at H.C. Wainwright

Biomea Fusion (BMEA) Presents Positive Clinical Data from Initial Cohorts of Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus

June 26, 2023 6:58 AM EDT

Biomea Fusion, Inc. (Biomea) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the presentation of new clinical data from the first two cohorts of patients with T2D enrolled in the Phase II portion of its ongoing Phase I/II clinical study (COVALENT-111) of BMF-219, the companys investigational oral covalent menin inhibitor.

Beta cell loss is a critical component of the etiology and pathogenesis of... More